Truist raised the firm’s price target on Chemours (CC) to $27 from $21 and keeps a Buy rating on the shares. Shares of covered TiO2 producers have seen significant momentum year-to-date, notes the analyst, who believes Chemours’ current valuation remains attractive given its higher North American exposure within TiO2 as well as its diversification into refrigerants.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CC:
- Chemours price target raised to $25 from $21 at Mizuho
- Neutral Outlook on Chemours as Stable Thermal Performance Offsets Titanium Dioxide Uncertainty and Below‑Consensus 2026 EBITDA
- Chemours Completes Major 2034 Senior Notes Refinancing
- Chemours price target raised to $21 from $17 at Mizuho
- Chemours Launches Upsized Senior Notes for Debt Refinancing